Calcitonin.
Nasal calcitonin is a newly approved treatment for established osteoporosis. Nasal calcitonin is safe, preventative, and may increase bone mass in the lumbar spine. Fracture efficacy data are not yet available, although preliminary results are promising. The dose of nasal calcitonin for the treatment of established osteoporosis is 200 IU daily. The dose for prevention of postmenopausal osteoporosis has not yet been established. Nasal calcitonin may be analgesic to bone and of benefit in glucocorticoid-induced osteoporosis.
Silverman
S L
SL
West Los Angeles VA Medical Center, UCLA, California 90073, USA.
D000281:Administration, Intranasal; D000700:Analgesics; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D002116:Calcitonin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008594:Menopause, Premature; D010024:Osteoporosis / Q000188:drug therapy* / Q000517:prevention & control*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000517:prevention & control*; D012474:Salmon; D013131:Spine / Q000187:drug effects / Q000503:physiopathology
D000700:Analgesics; D002116:Calcitonin